ASKA Pharmaceutical Holdings Co.,Ltd. (TYO:4886)
2,136.00
-18.00 (-0.84%)
Aug 25, 2026, 3:30 PM JST
TYO:4886 Revenue
ASKA Pharmaceutical Holdings had revenue of 17.38B JPY in the quarter ending June 30, 2026, a decrease of -10.03%. This brings the company's revenue in the last twelve months to 70.87B, up 5.61% year-over-year. In the fiscal year ending March 31, 2026, ASKA Pharmaceutical Holdings had annual revenue of 71.13B with 10.90% growth.
Revenue (ttm)
70.87B
Revenue Growth
+5.61%
P/S Ratio
0.86
Revenue / Employee
43.99M
Employees
1,611
Market Cap
61.17B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 71.13B | 6.99B | 10.90% |
| Mar 31, 2025 | 64.14B | 1.30B | 2.06% |
| Mar 31, 2024 | 62.84B | 2.38B | 3.94% |
| Mar 31, 2023 | 60.46B | 3.85B | 6.81% |
| Mar 31, 2022 | 56.61B | 1.43B | 2.58% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Towa Pharmaceutical | 279.94B |
| Sawai Group Holdings | 203.79B |
| KYORIN Pharmaceutical | 125.68B |
| Mochida Pharmaceutical | 122.04B |
| Kissei Pharmaceutical | 98.60B |
| Zeria Pharmaceutical | 91.12B |
| Kaken Pharmaceutical | 88.16B |
| Fuji Pharma | 60.11B |